価格表

在庫・価格 : 2025年04月30日 19時39分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Proprotein Convertase 9, Human, ELISA Kit, Quantikine (96well) <PCSK9, ELISA Kit>
データシート※最新のデータシートでない場合があります
DPC900 RSDアールアンドディー システムズ
R&D Systems, Inc.
1 kit ¥116,000
(未発注)
追加

在庫・価格 : 2025年04月30日 19時39分 現在

Proprotein Convertase 9, Human, ELISA Kit, Quantikine (96well) <PCSK9, ELISA Kit>

  • 商品コード:DPC900
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥116,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Chan JC et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 2009 Jun;106(24):9820-5
Chan JC et al
2009/01/01
Sample Type: Serum PubMed
2 Almontashiri NA et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE 2014;9(9):e106294
Almontashiri NA et al
2014/01/01
Sample Type: Plasma PubMed
3 Zhang Y et al. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis 2014;13:35
Zhang Y et al
2014/01/01
Sample Type: Plasma PubMed
4 Loregger A et al. A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol. Cell. Biol. 2015 Jan;36(2):285-94
Loregger A et al
2015/01/01
Sample Type: Cell Culture Supernates PubMed
5 Yang SH et al. Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives. Hypertens. Res. 2016 Aug;39(8):598-605
Yang SH et al
2016/01/01
Sample Type: Plasma PubMed
6 Ruscica M et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. J Am Heart Assoc 2017 May;6(5)
Ruscica M et al
2017/01/01
Sample Type: Plasma PubMed
7 Yuan F et al. Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies. J Am Heart Assoc 2018 Mar;7(6)
Yuan F et al
2018/01/01
Species: Porcine PubMed
8 Lebeau P et al. Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. J. Biol. Chem. 2018 May;293(19):7329-7343
Lebeau P et al
2018/01/01
Species: Human PubMed
9 Vlachopoulos C et al. Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias. Hellenic J Cardiol 2018 May;
Vlachopoulos C et al
2018/01/01
Species: Human PubMed
10 Zanni MV et al. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis 2017;4(4):ofx227
Zanni MV et al
2017/01/01
Species: Human PubMed
11 Gustafsen C et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 2017 09;8(1):503
Gustafsen C et al
2017/01/01
Species: Human PubMed
12 Carreras A et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol. 2019 01;17(1):4
Carreras A et al
2019/01/01
PubMed
13 Akcakaya P et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 2018 09;561(7723):416-419
Akcakaya P et al
2018/01/01
PubMed
14 Genga KR et al. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. EBioMedicine 2018 Dec;38:257-264
Genga KR et al
2018/01/01
PubMed
15 Ricci C et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep 2018 Feb;8(1):2267
Ricci C et al
2018/01/01
PubMed
16 Li C et al. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Sci Rep 2019 May;9(1):7693
Li C et al
2019/01/01
PubMed
17 Lebeau P et al. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. J. Biol. Chem. 2017 01;292(4):1510-1523
Lebeau P et al
2017/01/01
PubMed
18 Zimmer M et al. CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun 2017 06;1(4):311-325
Zimmer M et al
2017/01/01
PubMed
19 Papazyan R et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res 2018 06;59(6):982-993
Papazyan R et al
2018/01/01
PubMed
20 Cui CJ et al. Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1&#x3B1; and activating FoxO3a. J Transl Med 2020 05;18(1):195
Cui CJ et al
2020/01/01
PubMed
21 Cao YX et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. J Transl Med 2019 11;17(1):367
Cao YX et al
2019/01/01
PubMed
22 Lammi C et al. Trans-Epithelial Transport, Metabolism, and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met). Nutrients 2021 Mar;13(3)
Lammi C et al
2021/01/01
Species: Human PubMed
23 Melexopoulou C et al. PCSK9 and inflammatory biomarkers in the early post kidney transplantation period. Eur Rev Med Pharmacol Sci 2021 Jul;25(14):4762-4772
Melexopoulou C et al
2021/01/01
Species: Human PubMed
24 Ciric MZ et al. Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy. Nutrients 2021 Mar;13(3)
Ciric MZ et al
2021/01/01
Species: Human PubMed
25 Silvino JPP et al. Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? Thromb Res 2021 04;200:156-163
Silvino JPP et al
2021/01/01
Species: Human PubMed
26 Ibold B et al. Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice. Sci Rep 2021 01;11(1):2137
Ibold B et al
2021/01/01
Species: Human PubMed
27 Krahel JA et al. Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J Clin Med 2020 Mar;9(4)
Krahel JA et al
2020/01/01
Species: Human PubMed
28 Fasolato S et al. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med 2020 Sep;9(10)
Fasolato S et al
2020/01/01
Species: Human PubMed
  • No.: 1
  • 文献情報:
    Chan JC et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 2009 Jun;106(24):9820-5
    Chan JC et al
    2009/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Almontashiri NA et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE 2014;9(9):e106294
    Almontashiri NA et al
    2014/01/01
  • 備考:
    Sample Type: Plasma
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Zhang Y et al. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis 2014;13:35
    Zhang Y et al
    2014/01/01
  • 備考:
    Sample Type: Plasma
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Loregger A et al. A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol. Cell. Biol. 2015 Jan;36(2):285-94
    Loregger A et al
    2015/01/01
  • 備考:
    Sample Type: Cell Culture Supernates
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Yang SH et al. Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives. Hypertens. Res. 2016 Aug;39(8):598-605
    Yang SH et al
    2016/01/01
  • 備考:
    Sample Type: Plasma
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Ruscica M et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. J Am Heart Assoc 2017 May;6(5)
    Ruscica M et al
    2017/01/01
  • 備考:
    Sample Type: Plasma
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Yuan F et al. Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies. J Am Heart Assoc 2018 Mar;7(6)
    Yuan F et al
    2018/01/01
  • 備考:
    Species: Porcine
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Lebeau P et al. Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. J. Biol. Chem. 2018 May;293(19):7329-7343
    Lebeau P et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Vlachopoulos C et al. Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias. Hellenic J Cardiol 2018 May;
    Vlachopoulos C et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Zanni MV et al. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis 2017;4(4):ofx227
    Zanni MV et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Gustafsen C et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun 2017 09;8(1):503
    Gustafsen C et al
    2017/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Carreras A et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol. 2019 01;17(1):4
    Carreras A et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Akcakaya P et al. In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 2018 09;561(7723):416-419
    Akcakaya P et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Genga KR et al. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. EBioMedicine 2018 Dec;38:257-264
    Genga KR et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Ricci C et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep 2018 Feb;8(1):2267
    Ricci C et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Li C et al. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Sci Rep 2019 May;9(1):7693
    Li C et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Lebeau P et al. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. J. Biol. Chem. 2017 01;292(4):1510-1523
    Lebeau P et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Zimmer M et al. CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun 2017 06;1(4):311-325
    Zimmer M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Papazyan R et al. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res 2018 06;59(6):982-993
    Papazyan R et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Cui CJ et al. Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1&#x3B1; and activating FoxO3a. J Transl Med 2020 05;18(1):195
    Cui CJ et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Cao YX et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. J Transl Med 2019 11;17(1):367
    Cao YX et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Lammi C et al. Trans-Epithelial Transport, Metabolism, and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met). Nutrients 2021 Mar;13(3)
    Lammi C et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Melexopoulou C et al. PCSK9 and inflammatory biomarkers in the early post kidney transplantation period. Eur Rev Med Pharmacol Sci 2021 Jul;25(14):4762-4772
    Melexopoulou C et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Ciric MZ et al. Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy. Nutrients 2021 Mar;13(3)
    Ciric MZ et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Silvino JPP et al. Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? Thromb Res 2021 04;200:156-163
    Silvino JPP et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Ibold B et al. Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice. Sci Rep 2021 01;11(1):2137
    Ibold B et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Krahel JA et al. Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J Clin Med 2020 Mar;9(4)
    Krahel JA et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Fasolato S et al. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med 2020 Sep;9(10)
    Fasolato S et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed